Blog Archive
-
▼
2007
(17)
-
▼
October
(8)
- INNATE PHARMA, NEW PHASE IIa TRIAL WITH IPH 1101 I...
- BioAlliance Pharma, promising in vivo results for ...
- Flamel Technologies, Positive Results of a Phase I...
- bioMérieux’s VIDAS® B·R·A·H·M·S PCT® Assay A First...
- VIVALIS , FIRST RESEARCH LICENCE IN THE FIELD OF T...
- Biospace med, Total Solution to Orthopedic Imaging
- bioMerieux , Diagnosis and Prognosis of Heart Failure
- Transgene, therapeutic vaccine candidate TG4040 d...
-
▼
October
(8)
Tuesday, October 9, 2007
bioMerieux , Diagnosis and Prognosis of Heart Failure
October 1, 2007. bioMérieux, a global leader in the field of in vitro diagnostics, announces the launch of VIDAS® NT-proBNP, a CE-approved test that helps the diagnosis and prognosis of heart failure, developed by the company following a licensing agreement signed with Roche Diagnostics... bioMérieux's Press Release-